ORAI1 and breast carcinoma: In a study by Azimi et al. using MDA-MB-231 breast cancer cells, YM-58483 inhibited SOCE mediated by Orai1 with an IC50 value of 2.8 μM, while the compound was inactive against TRPV1, TRPM8, and CaV2.2 at concentrations up to 100 μM (Table 2) [121].